BDX - Becton Dickinson fingertip blood collection device wins FDA nod
2023-12-07 07:19:50 ET
Becton, Dickinson ( NYSE: BDX ) on Thursday announced that its novel blood collection device has received 510(k) clearances from the U.S. Federal Drug Administration.
BD MiniDraw Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger. The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing.
"Because the BD MiniDraw Collection System enables blood collection at non-traditional sites that may be more convenient—like your local pharmacy rather than a standalone lab—we can expand health equity and access, and make it easier for patients to get the blood tests they need both for preventative care and the management of chronic conditions," said Dave Hickey, executive vice president and president of Life Sciences for BD.
BD ( BDX ) plans to expand blood tests enabled by BD MiniDraw Collection System in the future.
More on Becton, Dickinson
- Following The Q4 Results, Becton, Dickinson and Company Is Still A Hold
- Becton, Dickinson And Company: Strong Q4 But Clouded By 75bps Growth Headwind From China In FY24
- Becton, Dickinson and Company (BDX) Q4 2023 Earnings Call Transcript
- Becton Dickinson names Ronald Silverman as CMO
- U.S. to distribute more free COVID tests
For further details see:
Becton, Dickinson fingertip blood collection device wins FDA nod